Location: Boston, MA
CIK: 0001637359 · Show all filings
Period: Q4 2016 (← Previous) (Next →)
Filing Date: Feb 10, 2017
Total Value: $123M (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | Paratek Pharmaceuticals | 2,600,410 | $40.05M | 32.5% | $34.18 | — | Common Stock | 699374302 |
| — | Juno Therapeutics | 1,229,512 | $23.18M | 18.8% | $52.22 | — | Common Stock | 48205A109 |
| — | Egalet | 2,889,926 | $22.11M | 17.9% | $5.98 | — | Common Stock | 28226B104 |
| — | FibroGen | 822,175 | $17.59M | 14.3% | $27.34 | — | Common Stock | 31572Q808 |
| — | Nabriva Therapeutics | 1,145,890 | $6.83M | 5.5% | $9.50 | — | Sponsored ADR | 62957M104 |
| — | Cidara Therapeutics | 495,050 | $5.149M | 4.2% | $10.40 | — | Common Stock | 171757107 |
| — | ESSA Pharma | 1,696,969 | $3.716M | 3.0% | $5.22 | — | Common Stock | 29668H104 |
| — | Pieris Pharmaceuticals | 1,697,384 | $2.376M | 1.9% | $1.83 | — | Common Stock | 720795103 |
| EDIT | Editas Medicine | 66,162 | $1.074M | 0.9% | $26.29 | -42.3% | Common Stock | 28106W103 |
| — | Dicerna Pharmaceuticals | 223,457 | $644K | 0.5% | $16.47 | — | Common Stock | 253031108 |
| — | CymaBay Therapeutics | 301,477 | $522K | 0.4% | $1.94 | — | Common Stock | 23257D103 |